Megakaryon Corporation
Latest round
- Series D
Last raised
- Feb 2020
Total raised
- $91M
Investors
- 22
About Megakaryon Corporation
Megakaryon Corporation, founded in 2011, specializes in producing human platelet products from induced pluripotent stem cells. Its notable development was the MEG-002 product, which aligns with patent advancements by Nakauchi-Eto.Megakaryon Corporation specializes in the production of human platelet products derived from induced pluripotent stem cells (iPS cells). The company's flagship offering, the MEG-002 product, is a genetically matched human platelet formulation that aims to provide a safe, reliable source for transfusions, addressing critical shortages in blood supply. This innovation leverages the groundbreaking Nakauchi-Eto patent, which facilitates the stable and large-scale production of platelets. The primary end users of these products include hospitals, blood banks, and medical facilities looking to enhance their transfusion capabilities, particularly in regions experiencing high demand for platelet therapies.Megakaryon Corporation generates revenue through its specialized products and services related to the manufacture and distribution of iPS cell-derived platelets. Business transactions are structured primarily on a B2B model, where hospitals and healthcare providers engage with the company to procure platelet products, potentially under long-term supply agreements or contracts for clinical trials. The pricing structure for these products is designed to reflect the quality and innovation associated with the MEG-002 offering, though specific pricing details are not publicly disclosed. The company aims to enhance efficiency in product manufacturing, enabling them to meet increasing market demands. Additionally, Megakaryon is exploring opportunities to expand its footprint beyond Japan to other global markets, although specific regions have yet to be defined. The company anticipates that these strategic initiatives will align with their goal of broadening access to their innovative platelet products.
Who invested in Megakaryon Corporation
22 investors across 4 rounds
See all investors in Megakaryon Corporation
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Megakaryon Corporation
Who invested in Megakaryon Corporation?
Megakaryon Corporation has 22 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Megakaryon Corporation raised?
Megakaryon Corporation has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Megakaryon Corporation last raise money?
Megakaryon Corporation's most recent round on record is a Series D, in Feb 2020.
What does Megakaryon Corporation do?
Megakaryon Corporation, founded in 2011, specializes in producing human platelet products from induced pluripotent stem cells.
Where is Megakaryon Corporation headquartered?
Megakaryon Corporation is headquartered in Kyoto-shi, Japan.
Which VCs invest in companies like Megakaryon Corporation?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Megakaryon Corporation's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series D
Raising like Megakaryon Corporation? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.